EUCTR2006-003374-10-DE进行中（未招募）不适用
An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subject Age: The subject is =2 months to =24 months of age at study entry.
- •2.Subject Diagnosis: The subject has a diagnosis of secondarily-infected traumatic lesion (SITL), secondarily-infected dermatoses (SID), or primary impetigo (bullous or non-bullous) that is suitable for treatment with topical antibacterial therapy:
- •SITL: The subject has a small laceration, sutured wound or abrasion, which has a secondary bacterial infection. The infected portion of the laceration or sutured wound should not exceed 10cm in length with surrounding erythema not extending more than 2cm from the edge of the wound. Abrasions should not exceed 2% of the total body surface area with surrounding erythema not extending more than 2cm from the edge of the abrasion.
- •SID: The subject has a diagnosis of inflammatory skin disease (i.e., dermatosis), such as atopic dermatitis or contact dermatitis, which has a secondary bacterial infection. The infected portion of the lesion(s) should not exceed 2% of the total body surface area.
- •Impetigo: The subject has a lesion or group of ?10 discrete localized lesions on otherwise healthy skin, characterized by red spots or blisters without crusts which later progress to lesions which ooze and form yellow or honey-colored crusts surrounded by an erythematous margin.
- •3.Subject SIRS Score: The subject has a total SIRS score of at least 8 (Appendix 1 Skin Infection Rating Scale)
- •4.Protocol Compliance: The parent/legal guardian is willing to comply with the protocol.
- •5.Informed Consent: The parent/legal guardian has given written informed, dated consent for the subject to participate in the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Previous Hypersensitivity: The subject has demonstrated a previous hypersensitivity reaction to pleuromutilin or any component of the ointment (refer to the Investigator Brochure for composition of Retapamulin ointment, 1%).
- •2.Prematurity: The subject was considered to be premature at birth (<37 weeks gestation).
- •3.Bite or puncture: The subject has a secondarily-infected animal/human bite, or a puncture wound.
- •4.Abscess: The subject has an abscess.
- •5.Unlikely to have S aureus or S pyogenes: The subject has a chronic ulcerative lesion that is unlikely to have Staphylococcus aureus or Streptococcus pyogenes as the causative agent.
- •6.Systemic Infection: The subject has systemic signs and symptoms of infection (such as fever; defined as a temperature equivalent to a rectal temperature greater than 101°F or 38.3°C).
- •7.Inappropriate for Topical Treatment: The subject has a bacterial skin infection which, due to area, depth or severity, in the opinion of the investigator, cannot be appropriately treated by a topical antibiotic.
- •8.Infected Lesion Type: The subject has more than one type of infected lesion as defined in the protocol.
- •9.Surgical Intervention: The subject requires surgical intervention for treatment of the infection prior to enrollment in the study, or is likely to require such intervention during the course of the study.
- •10.Other Topicals: The subject has applied any topical therapeutic agent (including glucocorticoid steroids, antibacterials or antifungals) directly to the infected wound/lesion, within 24 hours prior to study entry.
- •11.Systemic Antibacterials: The subject has received one or more days of treatment with a systemic antibacterial within 72 hours of study entry.
- •12.Systemic Corticosteriods: The subject is receiving systemic corticosteroids at a dose of >0.125mg/kg per day of prednisone (or the equivalent).
- •13.Serious Underlying Disease: The subject has a known, pre-existing, serious underlying disease that could be imminently life-threatening.
- •14.Other Investigational Drug: The subject has participated in any study using an investigational drug during the previous 30 days prior to entering the study.
- •15.Other Retapamulin Studies: The subject has been previously enrolled in this study or in any other study involving Retapamulin.
研究者
相似试验
进行中（未招募）
不适用
An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Monthsncomplicated skin and skin structure infectionsEUCTR2006-003374-10-NLGlaxoSmithKline Research & Development Ltd60
进行中（未招募）
1 期
A Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children with Myotonic DisordersMyotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM, type 1 or type 2)ICD-10 code G71.1MedDRA version: 21.1Level: LLTClassification code 10028658Term: Myotonic disordersSystem Organ Class: 100000004852EUCTR2019-003757-28-FRupin Europe GmbH14
进行中（未招募）
不适用
Evaluate Parasitological Clearance Rates And Pharmacokinetics Of The Combination Of Azithromycin And Chloroquine In Asymptomatic Pregnant Women With Falciparum Parasitemia In AfricaEUCTR2014-004906-14-Outside-EU/EEAPfizer Inc168
进行中（未招募）
3 期
An Open-Label, Non-Randomized Study to Assess the Safety and Efficacy of Leniolisib in Japanese Patients With Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Followed By an Open-Label Long-Term ExtensioJPRN-jRCT2061230036Bradt Jason3
进行中（未招募）
不适用
A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A (FVIII:C <1%)Severe hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 9.1Level: LLTClassification code 10018937Term: Haemophilia AEUCTR2008-008435-29-CZWyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company50